Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...
BioPharma Dive

Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results

The partners said the shot produced “clinically meaningful” efficacy despite missing its main study objective, a finding they ...

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme ...
BioSpace

Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint

The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% ...

Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal

There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot due to a lack of demand.

Pfizer’s Lyme vaccine shows strong efficacy, but misses mark in study

The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.
Becker's Hospital Review

Pfizer Lyme vaccine candidate heads to FDA

Pfizer Lyme vaccine candidate shows over 70% efficacy in phase 3 trial and moves forward with FDA regulatory submission.

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

March 23 (Reuters) - U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed ...